News
We send the latest information from SMC Laboratories.
NIDDK's publication in Purinergic Signaling
SMC announces that NIDDK (MD) has published the results of a study using the STAMTM mouse model in Purinergic …
Genfit announced that it will discontinue the Phase 3 NASH study and concentrate on the developmento of PBC therapeutics.
Genfit (France) announced on July 22, 2020, that it will discontinue Elafibranor's Phase 3 NASH clinical …
DURECT has published a news release regarding positive topline data from phase 1b study of DUR-928 in NASH
DURECT CORPORATION (USA) announced on May 26, 2020, that positive topline data was obtained in serum liver enz…
FDA rejects Intercept Pharma's drug for NASH for now
Intercept Pharmaceuticals, Inc. (USA) announced that it has received a notification from the FDA that it will …
Hepion pharma has publshed a pres releaes regarding the CRV431 efficacy evaluation study for kidney fibrosis we have provied.
Hepion pharma, which is our client, has announced the results of pharmacology study using a UUO mouse model. &…
Enzychem Lifesciences Corporation’s presentation at AASLD The Liver Meeting® 2019 in Boston.
SMC announced that Enzychem Lifesciences Corporation presented results of a study using STAM™ model at p…
Enyo Pharma SA’s presentation at AASLD The Liver Meeting® 2019 in Boston.
SMC announced that Enyo Pharma SA presented results of a study using STAM™ model at poster presentation …
Dr. Falk Pharma GmbH’s presentation at AASLD The Liver Meeting® 2019 in Boston.
SMC announced that Dr. Falk Pharma GmbH presented results of a study using STAM™ model at poster present…
NeuroVive Pharmaceutical’s publication on Cells.
SMC announced that NeuroVive Pharmaceutical has published the results of a study using STAM™ model on In…
Dokkyo Medical University’s publication on International Journal of Molecular Sciences.
SMC announced that Dokkyo Medical University has published the results of a study using STAM™ model on I…